Journal of Clinical Oncology, Vol 2, 8-15, Copyright © 1984 by American Society of Clinical Oncology
Cytologic evidence for gene amplification in methotrexate-resistant cells obtained from a patient with ovarian adenocarcinoma
JM Trent, RN Buick, S Olson, RC Horns Jr and RT Schimke
To analyze if methotrexate (MTX) resistance arises from gene amplification
in a patient treated clinically with MTX, the cytogenetic and drug
sensitivity profile of the tumor colony forming units (TCFUs) from a
58-year-old woman with stage III well-differentiated ovarian serous
adenocarcinoma was studied. This patient had not received treatment
directed against her tumor for nine months before this study, but had
received oral-dose MTX (2.5 mg, twice weekly) for three years for the
treatment of psoriasis. Analysis of TCFUs grown in nucleoside- free media
demonstrated MTX resistance at concentrations of up to 100 micrograms/mL
(2.2 X 10(-4)M). Cytologic evidence for dihydrofolate reductase (DHFR) gene
amplification in TCFUs was determined by in situ hybridization, using
radiolabeled cDNA to DHFR mRNA. Results localized the DHFR sequences to an
abnormally staining region present on chromosome 4q. This study supports
the notion that alterations in gene dosage (that is, gene amplification)
play a role in the development of drug resistance in spontaneous human
cancers.